Effect of first‑month specific therapy determines long‑term clinical outcome in patients with pulmonary arterial hypertension
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2018, Vol 3, Issue 6
Abstract
Efficacy of pulmonary arterial hypertension (PAH)-specific therapy may differ among the patients depending on the PAH aetiology. Aim: To compare the real‐life efficacy of PAH‐specific therapy between non‐congenital heart disease (non‐CHD) and CHD groups of PAH patients and to determine whether an early clinical response has an impact on prognosis. Methods: Clinical data from 41 PAH patients, 21 non‐CHD and 20 CHD patients, were included in the study. The WHO functional class (WHO‐FC), 6‐minute walk dis-tance (6MWD) and NT‐proBNP serum level were compared at baseline and after 1 and 7 months of PAH‐specific treatment. Only patients with unmodified PAH‐specific therapy during 7‐month follow‐up were enrolled in the study. Results: Baseline characteristics revealed higher WHO‐FC and increased [log e ]NT‐proBNP levels (7.74 ±1.05 vs 6.51 ±1.48; p = 0.008) in non‐CHD vs. CHD patients; baseline 6MWD was similar in both groups (283.3 ±148.5 m vs 339.2 ±114.7 m). Clinical improvement by at least one WHO‐FC after 1‐month treatment was observed more frequently in non‐CHD (55%) when compared with CHD patients (25%, p = 0.04) and was comparable (50% vs 50%) after 7‐month observation. Non‐CHD patients, who did not improve within 1 month of treatment were unlikely to achieve improvement after 7 months. The 6MWD increased during the first month of treatment in non‐CHD (p=0.009) and in CHD patients (p=0.006) when compared to baseline values and remained at this level after 7 months of treatment. [Log e ]NT‐proBNP levels markedly declined only in non‐CHD patients, who had an improvement in WHO‐FC (8.0 ±1.0 vs 7.4 ±1.1, p = 0.04) in the first month. In CHD patients, the decrease in [log e ]NT‐proBNP level was seen (6.5 ± 1.5 vs 6.1 ±1.5, p = 0.04) only within a 1‐month observation. Conclusion: Efficacy of 1‐month PAH‐specific therapy is aetiology‐dependent and determines clinical outcome in patients with PAH. JRCD 2018; 3 (6): 198–203.
Authors and Affiliations
Adrianna Nowak, Karolina Bula, Karol Głowacki, Wojciech Gawin, Konstantinos Nechoritis, Marek Grabka, Katarzyna Mizia‐Stec
Keywords
Related Articles
- EP ID EP286458
- DOI 10.20418/jrcd.v3i6.316.g223
- Views 99
- Downloads 0
Genetics and genetic testing in pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a rare disease with a high mortality and complex pathomechanism. Recent studies suggest an important role of genetic factors in the development of PAH. It was shown that patients...
Cardiopulmonary exercise tests in rare cardiovascular heart diseases
Cardiopulmonary exercise testing (CPET) is commonly used in clinica practice for both functional and diagnostic assessments of patients with cardiovascular and pulmonary disease. It provides assessment of the integrative...
Development of the European Network in Orphan Cardiovascular Diseases. EU Project inauguration
Both international and Polish cardiology community warmly welcomed our prior international project entitled Establishing a European Network for Orphan Cardiovascular Diseases (European Regional Development Fund and Małop...
World Rare Disease Day – 29th of February 2016 III Conference of Rare Cardiovascular Diseases at John Paul II Hospital in Krakow
The third Conference of Rare Cardiovascular Diseases took place at the John Paul II Hospital in Krakow, Poland on the 29th of February 2016. The conference was organized as part of the World Rare Disease Day 2016 annuall...
Report from the European Society of Cardiology Congress 2016 in Rome
N/A